Systemic inflammation regulates microglial responses to tissue damage in vivo

GLIA

Volumn 62, Issue 8, 2014, Pages 1345-1360

  Gyoneva, Stefka ^a   Davalos, Dimitrios ^b   Biswas, Dipankar ^c   Swanger, Sharon A ^a   Garnier Amblard, Ethel ^a   Loth, Francis ^c   Akassoglou, Katerina ^b   Traynelis, Stephen F ^a  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c The University of Akron   (United States)

Author keywords

Imaging; Microglia; Motility; Neuroinflammation

Indexed keywords

INTERLEUKIN 1BETA; LIPOPOLYSACCHARIDE; MESSENGER RNA; PRELADENANT; TUMOR NECROSIS FACTOR ALPHA; ADENOSINE A1 RECEPTOR; ADENOSINE A2A RECEPTOR; ADENOSINE A3 RECEPTOR; IMMUNOLOGIC FACTOR; PYRIMIDINE DERIVATIVE; TRIAZOLE DERIVATIVE;

ALGORITHM; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BRAIN DAMAGE; BRAIN FUNCTION; CELL DEATH; CELL MOTILITY; CONTROLLED STUDY; HETEROLOGOUS EXPRESSION; IN VITRO STUDY; IN VIVO STUDY; LASER SURGERY; MICROGLIA; MORPHOLOGICAL TRAIT; MOUSE; NERVOUS SYSTEM INFLAMMATION; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; TISSUE INJURY; ANIMAL; BRAIN CORTEX; CELL MOTION; CULTURE TECHNIQUE; DRUG EFFECTS; FEMALE; IMMUNOMODULATION; INFLAMMATION; LASER; MALE; METABOLISM; PATHOLOGY; PATHOPHYSIOLOGY; PHYSIOLOGY; SEPSIS; TRANSGENIC MOUSE;

ANIMALS; CELL CULTURE TECHNIQUES; CELL MOVEMENT; CEREBRAL CORTEX; FEMALE; IMMUNOLOGIC FACTORS; INFLAMMATION; LASERS; LIPOPOLYSACCHARIDES; MALE; MICE, TRANSGENIC; MICROGLIA; NEUROIMMUNOMODULATION; PYRIMIDINES; RECEPTOR, ADENOSINE A1; RECEPTOR, ADENOSINE A2A; RECEPTOR, ADENOSINE A3; SEPSIS; TRIAZOLES;

EID: 84902264814     PISSN: 08941491     EISSN: 10981136     Source Type: Journal    
DOI: 10.1002/glia.22686     Document Type: Article

References (61)

1. Akiyama H, Barger S, Barnum S, Bradt B, Bauer J, Cole GM, Cooper NR, Piet E, Emmerling M, Fiebich BL, Finch CE, Frautschy S, Griffin WST, Hampel H, Hull M, Landreth G, Lue L-F, Mrak R, Mackenzie IR, McGeer PL, O'Banion MK, Pachter J, Pasinetti G, Plata-Salaman C, Rogers J, Rydel R, Shen Y, Streit W, Strohmeyer R, Tooyoma I, Van Muiswinkel FL, Veerhuis R, Walker D, Webster S, Wegrzyniak B, Wenk G, Wyss-Coray T. 2000. Inflammation and Alzheimer's disease. Neurobiol Aging 21:383-421.
2. 2A receptors. Exp Neurol 228:160-164.
3. Bolmont T, Haiss F, Eicke D, Radde R, Mathis CA, Klunk WE, Kohsaka S, Jucker M, Calhoun ME. 2008. Dynamics of the microglial/amyloid interaction indicate a role in plaque maintenance. J Neurosci 28:4283-4292.
4. Carta AR, Kachroo A, Schintu N, Xu K, Schwarzschild MA, Wardas J, Morelli M. 2009. Inactivation of neuronal forebrain A2A receptors protects dopaminergic neurons in a mouse model of Parkinson's disease. J Neurochem 111:1478-1489.
5. 2A adenosine receptor inactivation in a model of Parkinson's disease. J Neurosci 21:RC143.
6. Colton CA, Wilcock DM. 2010. Assessing activation states in microglia. CNS Neurol Disord Drug Targets 9:174-191.
7. Cunningham C. 2013. Microglia and neurodegeneration: The role of systemic inflammation. Glia 61:71-90.
8. Davalos D, Grutzendler J, Yang G, Kim JV, Zuo Y, Jung S, Littman DR, Dustin ML, Gan W-B. 2005. ATP mediates rapid mecroglial response to local brain injury in vivo. Nat Neurosci 8:752-758.
9. Davalos D, Ryu JK, Merlini M, Baeten KM, Le Moan N, Petersen MA, Deerinck TJ, Smirnoff DS, Bedard C, Hakozaki H, Murray SG, Ling JB, Lassmann H, Degen JL, Ellisman MH, Akassoglou K. 2012. Fibrinogen-induced perivascular microglial clustering is required for the development of axonal damage in neuroinflammation. Nat Commun 3:1227-1242.
10. Edison P, Archer HA, Gerhard A, Hinz R, Pavese N, Turkheimer FE, Hammers A, Tai YF, Fox N, Kennedy A, Rossor M, Brooks DJ. 2008. Microglia, amyloid, and cognition in Alzheimer's disease: An [11C](R)PK11195-PET and [11C]PIB-PET study. Neurobiol Dis 32:412-419.
11. Etminan M, Gill S, Samii A. 2003. Effect of non-steroidal anti-inflammatory drugs on risk of Alzheimer's disease: systematic review and meta-analysis of observational studies. Br Med J 327:128.
12. Färber K, Markworth S, Pannasch U, Nolte C, Prinz V, Kronenberg G, Gertz K, Endres M, Bechmann I, Enjyoji K, et al. 2008. The endonucleotidase cd39/ENTPDase1 modulates purinergic-mediated microglial migration. Glia 56:331-341.
13. Franchetti P, Cappellacci L, Marchettu S, Trincavelli L, Martini C, Mazzoni MR, Lucacchini A, Grifantini M. 1998. 2'-C-methyl analogues of selective adenosine receptor agonists: synthesis and binding studies. J Med Chem 41:1708-1715.
14. Fredholm BB, Irenius E, Kull B, Schulte G. 2001. Comparison of the potency of adenosine as an agonist at human adenosine receptors expressed in Chinese hamster ovary cells. Biochem Pharmacol 61:443-448.
15. 3-selective adenosine agonists. J Med Chem 37:636-646.
16. Gao X, Chen H, Schwarzschild MA, Ascherio A. 2011. Use of ibuprofen and risk of Parkinson disease. Neurology 76:863-869.
17. 11C](R)-PK11195 PET in idiopathic Parkinson's disease. Neurobiol Dis 21:404-412.
18. Gyoneva S, Traynelis SF. 2013. Norepinephrine modulates the motility of resting and activated microglia via different adrenergic receptors. J Biol Chem 288:15291-15302.
19. Hanisch U-K, Kettenmann H. 2007. Microglia: Active sensor and versatile effector cells in the normal and pathologic brain. Nat Neurosci 10:1387-1394.
20. Hasko G, Pacher P, Vizi ES, Illes P. 2005. Adenosine receptor signaling in the brain immune system. Trends Pharmacol Sci 26:511-516.
21. Hauser RA, Cantillon M, Pourcher E, Micheli F, Mok V, Onofrj M, KHuyck S, Wolski K. 2011. Preladenant in patients with Parkinson's disease and motor fluctuations: A phase 2, double blind, randomised trial. Lancet Neurol 10:221-229.
22. 12 receptor regulates microglial activation by extracellular nucleotides. Nat Neurosci 9:1512-1519.
23. 2A receptor antagonists preladenant and SCH 412348 [7-[2-[4-2, 4-difluorophenyl]-1-piperazinyl]-2-(2-furanyl)-7H-pyrazolo[4, 3-e][1, 2, 4]triazolo[1, 5-c]pyrimidin-5-amine] in rodent models of movement disorders and depression. J Pharmacol Exp Therap 330:294-303.
24. i/o-coupled P2Y receptors. J Neurosci 21:1975-1982.
25. SC, even upon LPS stimulation. Glia 58:2017-2030.
26. Hutchinson AJ, Webb RL, Oei HH, Ghai GR, Zimmerman MB, Williams M. 1989. CGS 21680, an A2 selective adenosine receptor agonist with preferential hypotensive activity. J Pharmacol Exp Therap 251:47-55.
27. Jiang J, Quan Y, Ganesh T, Pouliot WA, Dudek FE, Dingledine R. 2013. Inhibition of the prostaglandin receptor EP2 following status epilepticus reduces delayed mortality and brain inflammation. Proc Natl Acad Sci USA 110:3591-3596.
28. Jones CK, Bubser M, Thompson AD, Dickerson JW, Turle-Lorenzo N, Amalric M, Blobaum AL, Bridges TM, Morrison RD, Jadhav S, Engers DW, Italiano K, Bode J, Daniels JS, Lindsley CW, Hopkins CR, Conn PJ, Niswender CM. 2012. The metabotropic glutamate receptor 4-positive allosteric modulator VU0364770 produces efficacy alone and in combination with L-DOPA or and adenosine 2A antagonist in preclinical rodent models of Parkinson's disease. J Pharmacol Exp Therap 340:404-421.
29. 3CR1 function by targeted deletion and green fluorescent protein reporter gene insertion. Mol Cell Biol 20:4106-4114.
30. Kettenmann H, Kirchhoff F, Verkhratsky A. 2013. Microglia: New roles for the synaptic stripper. Neuron 77:10-18.
31. Krabbe G, Halle A, Matyash V, Rinnenthal JL, Eom GD, Berngardt U, Miller KR, Prokop S, Kettenman H, Heppner FL. 2013. Functional impairment of microglia coincides with beta-amyloid deposition in mice with Alzheimer-like pathology. PloS One 8:e60921.
32. Liu Y, Hao W, Letiembre M, Walter S, Kulanga M, Neumann H, Fassbender K. 2006. Suppression of microglial inflammatory activity by myelin phagocytosis: Role of p47-PHOX-mediated generation of reactive oxygen species. J Neurosci 26:12904-12913.
33. Magnus T, Chan A, Grauer O, Toyka KV, Gold R. 2001. Microglial phagocytosis of apoptotic inflammatory T cells leads to down-regulation of microglial immune activation. J Immunol 167:5004-5010.
34. McDonald J. 2009. Handbook of biological statistics, 2nd ed. Baltimore, MD: Sparky House Publishing.
35. McGeer PL, Itagaki S, Akiyama H, McGeer EG. 1988. Rate of cell death in Parkinsonims indicates active neuropathological process. Ann Neurol 24:574-576.
36. 2a receptor antagonism reduces JNK activation in oligodendrocytes after cerebral ischaemia. Brain 132:1480-1495.
37. Morelli M, Carta AR, Kachroo A, Schwarzschild MA. 2010. Pathophysiological roles for purines: Adenosine, caffeine and urate. Prog Brain Res 183:183-208.
38. Murta V, Ferrari CC. 2013. Influence of peripheral inflammation on the progression of multiple sclerosis: Evidence from the clinic and experimental animal models. Mol Cell Neurosci 53:6-13.
39. 2A receptor antagonists: Arylpiperazine derivatives of pyrazolo[4, 3-e]-1, 2, 4-triazolo[1, 5-c]pyrimidines. Bioorg Med Chem Lett 17:1376-1380.
40. Nimmerjahn A, Kirchhoff F, Helmchen F. 2005. Resting microglial cells are highly dynamic surveillants of brain parenchyma in vivo. Science 308:1314-1318.
41. Ohsawa K, Sanagi T, Nakamura Y, Suzuki E, Inoue K, Kohsaka S. 2012. Adenosine A3 receptor is involved in ADP-induced microglial process extension and migration. J Neurochem 121:217-227.
42. 2A receptor mediates microglial process retraction. Nat Neurosci 12:872-878.
43. 2A receptor in ischemia. Ann NY Acad Sci 939:74-84.
44. Perry VH, Cunningham C, Holmes C. 2007. Systemic infections and inflamamtion affect chronic neurodegeneration. Nat Rev Immunol 7:161-167.
45. Perry VH, Newman TA, Cunningham C. 2003. The impact of systemic infection on the progression of neurodegenerative disease. Nat Rev Neurosci 4:103-112.
46. Prinz M, Priller J, Sisodia SS, Ransohoff RM. 2011. Heterogeneity of CNS myeloid cells and their roles in neurodegeneration. Nat Neurosci 14:1-9.
47. Qin L, Wu X, CBlock ML, Liu Y, Breese GR, Hong J-S, Knapp DJ, Crews FT. 2007. Systemic LPS causes chronic neuroinflammation and progressive neurodegenration. Glia 55:453-462.
48. 2A receptors in Parkinson's disease. Trends Neurosci 29:647-654.
49. Semmler A, Frisch C, Debier T, Ramanathan M, Okulla T, Klockgether T, Heneka MT. 2007. Long-term cognitive impairment, neuronal loss and reduced cortical cholinergic innervation after recovery from sepsis in a rodent model. Exp Neurol 204:733-740.
50. Semmler A, Hermann S, Mormann F, Weberpals M, Paxian SA, Okulla T, Schäfers M, Kummar MP, Klockgether T, Heneka MT. 2008. Sepsis causes neuroinflammation and concomitant decrease of cerebral metabolism. J Neuroinflamm 5:38.
51. Semmler A, Okulla T, Sastre M, Dumitrescu-Ozimek L, Heneka MT. 2005. Systemic inflammation induces apoptosis with variable vulnerability of different brain regions. J Chem Neuroanat 30:144-157.
52. Tansey MG, Goldberg MS. 2010. Neuroinflammation in Parkinson's disease: Its role in neuronal death and implications for therapeutic intervention Neurobiol Dis 37:510-518.
53. Tremblay M-E, Stevens B, Sierra A, Wake H, Bessis A, Nimmerjahn A. 2011. The role of microglia in the healthy brain. J Neurosci 31:16064-16069.
54. Venneti S, Lopresti BJ, Wiley CA. 2013. Molecular imaging of microglia/macrophages in the brain. Glia 61:10-23.
55. Voll RE, Herrmann M, Roth EA, Stach C, Kalden JR. 1997. Immunosuppresive effects of apoptotic cells. Nature 390:350-351.
56. von Kugelgen I, Wetter A. 2000. Molecular pharmacology of P2Y-receptors. Naunyn-Schmiedebergs Arch Pharmacol 362:310-323.
57. Weberpals M, Hermes M, Hermann S, Kummar MP, Terwel D, Semmler A, Berger M, Schäfers M, Heneka MT. 2009. NOS2 gene deficiency protects from sepsis-induced long-term cognitive deficits. J Neurosci 29:14177-14184.
58. L-3, 4-dihyrdoxyphenylalanine-induced dyskinesia in hemiparkinsonian mice. J Neurosci 26:13548-13555.
59. 2A receptor antagonists in Parkinson's disease. Pharmacol Therap 105:267-310.
60. 2A receptor antagonists exert motor and neuroprotective effects by distinct cellular mechanisms. Ann Neurol 63:338-346.
61. Zimmermann H. 1994. Signalling via ATP in the nervous system. TINS 17:420-426.